- Published on
Toxicology – Valproic Acid
Description
Valproic acid is an anticonvulsant medication used for the treatment of seizure disorders, bipolar affective disorder, and migraine headache.
Forms and Uses
Pharmaceutical preparations include sodium valproate and divalproex sodium.
For seizure disorders, the usual adult starting dose is approximately 15 mg/kg/day orally, divided into one to three doses, with gradual increases up to a maximum of about 60 mg/kg/day.
For migraine prophylaxis, adult dosing generally ranges from 250–1,000 mg/day orally.
For mania, an adult starting dose of approximately 750 mg/day may be used and titrated upward, with a maximum of about 60 mg/kg/day divided into several doses.
Toxic Dose
The toxic dose is variable.
Adverse effects may occasionally occur at concentrations close to the therapeutic range, particularly in individuals who are not chronically taking valproate.
Severe toxicity, including coma, has been reported after very large pediatric ingestions. One reported infant ingested approximately 750 mg/kg.
Pathophysiology
The exact therapeutic and toxic mechanisms of valproic acid are not completely understood.
One important action is an increase in brain concentrations of:
Gamma-aminobutyric acid (GABA)
which contributes to CNS inhibitory activity.
In overdose, excessive CNS depression becomes the dominant manifestation.
Epidemiology
Valproic acid poisoning is relatively uncommon.
Most overdoses produce mild toxicity, while severe poisoning and death are generally associated with massive ingestions or important coingestants.
Causes
Most significant overdoses are intentional.
In very young children, inappropriate exposure may raise concern for neglect.
In older children, adolescents, or adults, intentional self-poisoning should be considered when appropriate.
Risk Factors
Patients with underlying cardiovascular disease may be more susceptible to severe cardiovascular effects during significant poisoning.
Drug and Disease Interactions
Coadministration with other:
Sedatives, hypnotics, anticonvulsants, or CNS depressants
may increase CNS depression.
Therapeutic use with medications such as:
Cimetidine, ranitidine, aspirin, and isoniazid
may increase valproate concentrations.
Use with some other anticonvulsants may increase concentrations of valproate metabolites and potentially contribute to hepatic injury.
Pregnancy and Lactation
The historical FDA classification listed valproic acid as Pregnancy Category D.
Evidence of fetal risk exists.
Valproic acid is a known human teratogen and has been associated with an increased risk of:
Neural tube defects, particularly spina bifida
and
Minor craniofacial abnormalities.
The historical estimate for spina bifida risk was approximately 1%–2%.
Differential Diagnosis
Other toxic causes of CNS depression include:
Barbiturates, other anticonvulsants, ethanol, sedative-hypnotics, and many other CNS depressants.
Non-toxicologic causes include:
Metabolic abnormalities, electrolyte disturbances, intracranial mass or hemorrhage, and infection.
Clinical Features
Mild CNS depression is common after overdose.
With increasing severity, patients may progress to:
Lethargy → coma → respiratory depression → hypotension
Fever is uncommon.
HEENT
Pinpoint pupils have occasionally been reported, although this is not a common finding.
Cardiovascular Effects
Severe overdose may cause:
Profound hypotension
and, rarely:
Cardiac arrest
Cardiac arrest usually occurs secondary to severe respiratory failure or profound systemic toxicity.
Pulmonary Effects
Respiratory depression may progress to respiratory failure in severe poisoning.
Gastrointestinal Effects
Pancreatitis has been reported after severe overdose.
Pancreatitis may also occur as an adverse effect during chronic therapeutic treatment.
Hepatic Effects
Hepatitis may develop during chronic valproic acid therapy and can occasionally be fatal.
This complication occurs particularly in children during the first several months of therapy, especially when multiple anticonvulsants are being used.
After an acute overdose, mild elevations in hepatic enzymes may occasionally occur.
Renal Effects
Acute renal failure is uncommon and is generally associated with severe hypotension or other complications of major poisoning.
Hematologic Effects
Rare hematologic abnormalities after overdose include:
Anemia
Thrombocytopenia
and
Leukopenia
Leukopenia may also occur during chronic therapeutic use.
Fluids and Electrolytes
Rare abnormalities after acute overdose include:
Hypernatremia
and
Hypocalcemia.
Neurologic Effects
CNS depression is the most common neurologic manifestation.
Severity may range from:
Drowsiness and lethargy
to
Profound coma.
Hypertonia and seizures have also been reported after overdose.
Chronic therapeutic use has occasionally been associated with:
Parkinsonian symptoms
and
Cerebellar atrophy.
Acid–Base Effects
Metabolic acidosis may occur in severe poisoning.
This is generally associated with significant hypotension or systemic compromise.
Serum Valproic Acid Concentration
Serum valproic acid concentration is an important investigation.
The historical therapeutic range is:
50–100 μg/mL
Toxic effects may begin to occur when concentrations rise above approximately:
100 μg/mL
although the clinical condition remains important when interpreting the concentration.
Laboratory Evaluation
In patients with altered mental status or significant poisoning, useful tests include:
Serum electrolytes
Glucose
BUN and creatinine
to evaluate metabolic abnormalities and renal function.
Respiratory and Acid–Base Evaluation
Pulse oximetry and arterial blood gases may be useful in symptomatic patients to evaluate:
Hypoxia
Respiratory depression
and
Metabolic acidosis.
Other Anticonvulsant Levels
When multiple anticonvulsants may have been involved, measurement of other anticonvulsant concentrations can help assess the cause of CNS depression.
CBC, Platelets, and Pancreatic Evaluation
In severe poisoning, useful studies may include:
CBC
Platelet count
and
Serum amylase
to assess for bone marrow suppression or pancreatitis.
ECG and Coingestant Screening
An ECG may be obtained in significant overdose.
In deliberate or uncertain ingestions, acetaminophen and salicylate concentrations may be useful to detect occult coingestion.
Additional Diagnostic Testing
Depending on the presentation, additional investigations may include:
Serum ethanol
Urine toxicology screening
Lumbar puncture
Bacterial cultures
Chest radiography
or
Head CT
to evaluate other causes or complications of CNS depression.
Treatment
Management is primarily supportive.
The major priorities are:
Airway protection + respiratory support + hemodynamic support
The dose, formulation, timing of ingestion, and possibility of coingestants should be determined whenever possible.
When to Seek Toxicology Assistance
Poison-center or toxicology consultation is appropriate when:
Coma, respiratory depression, hypotension, or other severe effects develop
or when:
The clinical picture is inconsistent with valproic acid poisoning or important coingestants are suspected.
Referral to a Health-Care Facility
Medical assessment is appropriate when:
Symptoms are present
Intentional overdose is suspected
The history is unreliable
or
Coingestants or underlying disease complicate the presentation.
Admission
ICU-level treatment may be required for patients with:
Significant altered mental status
or
Hemodynamic instability.
Decontamination – Out of Hospital
Vomiting should not be induced.
CNS depression may develop and increase the risk of aspiration.
Decontamination – In Hospital
The historical treatment approach included gastric lavage after a large recent ingestion or when severe effects were present.
Activated charcoal was also recommended after a substantial recent ingestion.
Activated Charcoal
A single dose of activated charcoal was historically used after significant recent ingestion.
Additional doses were sometimes considered when valproate concentrations continued to rise.
Multiple-Dose Activated Charcoal
Case reports suggested that repeated activated charcoal might shorten the elimination half-life.
However, controlled studies were lacking, and routine use was not recommended.
One or two additional doses were sometimes considered when serum valproate concentrations continued to rise.
Whole-Bowel Irrigation
Whole-bowel irrigation was recommended when serum concentrations continued to increase despite initial gastrointestinal decontamination.
It was considered particularly useful after ingestion of:
Enteric-coated products
or
Divalproex-containing preparations.
Hemodialysis
Valproic acid is normally highly protein bound.
At toxic concentrations, however, the proportion of unbound drug increases substantially.
Hemodialysis has been used in severe cases.
Routine use was not recommended in the original text, but it was considered potentially useful in patients with:
Severe poisoning
and
Hemodynamic instability.
Hemoperfusion
Hemoperfusion has also been used in severe valproic acid poisoning.
Routine use was not recommended, but it was considered an option in patients with severe toxicity and hemodynamic instability.
Antidote
There is no specific antidote for valproic acid poisoning.
Treatment is primarily supportive.
Naloxone
Naloxone has occasionally been reported to improve CNS depression after valproic acid overdose.
However, the response has been inconsistent.
The historical adult starting dose was:
Naloxone 2 mg IV
Hypotension
If hypotension is associated with bradycardia, atropine may be considered.
The historical supportive approach included:
10–20 mL/kg of 0.9% saline intravenously
followed by additional fluids as clinically appropriate.
A vasopressor may be added if hypotension persists.
Seizures
Airway patency should first be ensured.
Benzodiazepines are used for initial seizure control.
If seizures persist or recur, another anticonvulsant such as phenobarbital may be added.
Patient Monitoring
Symptomatic patients should have continuous monitoring of:
Respiratory status
and
Cardiac function.
Complications from prolonged hypotension or hypoxia are uncommon when supportive care is provided promptly.
Expected Course and Prognosis
Most patients recover within approximately:
24–48 hours
after mild or moderate poisoning.
Patients with severe CNS depression or hypotension may require:
4–5 days or longer
before full recovery.
Delayed Absorption
A major concern with divalproex sodium is delayed absorption.
Peak serum concentrations and onset of symptoms may be delayed for 8 hours or longer.
This is especially important after ingestion of delayed-release or enteric-coated preparations.
Discharge From the Emergency Department
Asymptomatic patients with declining serum concentrations may be considered for discharge after an adequate observation period.
The original text suggests approximately:
6–8 hours
provided the patient remains clinically well.
Psychiatric evaluation should be completed when indicated.
Discharge From Hospital
Hospitalized patients may be discharged when:
Hypotension has resolved
Respiratory depression has resolved
CNS depression has significantly improved
and
Serum valproate concentrations are decreasing.
Psychiatric evaluation should be completed when appropriate.
Important Pitfalls
A normal or modest early valproate concentration does not necessarily exclude later toxicity.
Divalproex and enteric-coated preparations may produce delayed peaks.
CNS depression should not automatically be attributed to valproic acid.
Other sedatives, anticonvulsants, ethanol, neurologic disease, infection, and metabolic abnormalities should be considered.
Severe hypotension, respiratory depression, or coma require aggressive supportive care.
Serum valproate concentrations should be followed until a clear downward trend is established after a significant overdose.
High-Yield Toxicology Pearls
Valproic acid overdose primarily causes CNS depression.
The typical progression is:
Lethargy → coma → respiratory depression ± hypotension
The historical therapeutic serum range is:
50–100 μg/mL
and toxicity may begin above approximately:
100 μg/mL
Severe overdose may cause:
Profound hypotension
Respiratory failure
Seizures
Metabolic acidosis
Pancreatitis
and rarely:
Bone marrow suppression or acute renal failure.
Valproic acid is usually highly protein bound, but:
Protein binding decreases at toxic concentrations, increasing the free drug fraction.
Delayed-release and divalproex preparations may cause:
Delayed peak concentrations and delayed clinical deterioration.
The main treatment is:
Airway support + respiratory support + hemodynamic support
There is:
No specific antidote.
Naloxone has occasionally improved CNS depression, although responses are inconsistent.
Hemodialysis and hemoperfusion have been used in severe poisoning, particularly when marked toxicity and hemodynamic instability are present.
The most important clinical warning is:
After divalproex overdose, an initially reassuring level does not guarantee safety—the concentration and CNS depression may continue to rise for many hours.